SCHEMBL4293493

SCHEMBL4293493

CS(=O)(=O)Nc1nccc(Oc2ccc3[nH]ccc3c2)n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.44
KDR P35968 10/20 0.44
PIP4K2A P48426 1/20 0.43
PIP4K2B P78356 1/20 0.43
SYK P43405 1/20 0.40
FLT1 P17948 2/20 0.40
FGFR1 P11362 1/20 0.40
FLT4 P35916 1/20 0.40
FLT3 P36888 1/20 0.40
MERTK Q12866 1/20 0.40
NTRK2 Q16620 1/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37
MAOA P21397 1/20 0.37
RET P07949 1/20 0.37
BPTF Q12830 1/20 0.37
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4284781 0.87 KDR (0.61) KDRSYKFLT1FGFR1FLT4
SCHEMBL4285074 0.84 PIK3CD (0.48) JAK2KDRFLT1FGFR1FLT4
SCHEMBL13805558 0.79 KDR (0.41) JAK2KDRFLT1FGFR1FLT4
SCHEMBL4287622 0.78 SYK (0.48) JAK2KDRSYKFLT1FGFR1
SCHEMBL4281016 0.78 KDR (0.54) JAK2KDRSYKFLT1FGFR1
SCHEMBL18756060 0.77 KDR (0.42) KDRSYKTHRATHRBMAOA
SCHEMBL2777360 0.77 KDR (0.45) JAK2KDRFLT1FLT4MAOA
SCHEMBL4287649 0.76 SYK (0.47) JAK2KDRSYKFLT1FGFR1
SCHEMBL2509875 0.76 AHR (0.45) JAK2KDRSYKTHRATHRB
SCHEMBL4287689 0.76 KDR (0.50) KDRSYKFLT1FGFR1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US claimed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP claimed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO claimed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149467-A1 Tyrosine Kinase Inhibitors ABL1, MET, ERBB2 JAK2 14/4885KDR 165/4885PIP4K2A 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.